JGC
MLYS icon

J. Goldman & Co’s Mineralys Therapeutics MLYS Stock Holding History

J. Goldman & Co’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-121,500
Closed -$1.93M – 570
2025
Q1 		$1.93M Buy
+121,500
New +$1.4M 0.05% 302

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

J. Goldman & Co's MLYS Position: Q1 2026 in Review

J. Goldman & Co increased its Mineralys Therapeutics (MLYS) stake by 99% in Q1 2026, buying an estimated $1.37M and bringing the position to 94,101 shares worth $2.55M. The position accounts for 0.07% of the portfolio, ranked #287.

J. Goldman & Co first reported a position in MLYS in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.83M in Q1 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • J. Goldman & Co held 94,101 shares of Mineralys Therapeutics worth $2.55M as of Q1 2026.
  • J. Goldman & Co bought 46,813 Mineralys Therapeutics shares in Q1 2026, an estimated $1.37M.
  • Mineralys Therapeutics made up 0.07% of J. Goldman & Co's portfolio in Q1 2026, its #287 holding.
  • J. Goldman & Co first reported a position in Mineralys Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • J. Goldman & Co's Mineralys Therapeutics position peaked at $2.83M in Q1 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.